Popular Trials
Alkylating agents
Chemoradiotherapy + Stem Cell Transplant for Blood Cancers
Recruiting1 awardPhase 1 & 2
Duarte, California
This trial is giving chemotherapy drugs and HT before a donor stem cell transplant to see if it helps stop the growth of cancer cells and also helps stop the patient's immune system from rejecting the donor's stem cells.
Dietary Supplement
Vitamin C for Myelodysplastic Syndrome
Recruiting0 awards3 criteria
Los Angeles, California
This trial tests if taking vitamin C daily can help patients with certain low-risk blood cancers. These patients often have low vitamin C levels, which might affect their DNA. By boosting vitamin C, the study aims to see if it can improve DNA health and slow cancer progression. Vitamin C has been studied for its potential effects on cancer prevention and treatment, with some evidence suggesting it may improve quality of life and defense reactions in cancer patients.
Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor
JNJ-64619178 for Cancer
Recruiting1 awardPhase 1
Sarasota, Florida
This trial is testing a new cancer drug to see what doses are tolerated by patients with different types of cancer, including lymphoma and solid tumors. The goal is to also find out what doses of the drug might be effective in treating these cancers.
Popular Filters
Trials for MDS Patients
Antimetabolites
Cord Blood Transplant for Blood Diseases
Recruiting1 awardPhase 1
Rochester, New York
This trial uses stem cells from a baby's umbilical cord to treat patients who need new healthy stem cells. Patients first get strong medicine to clear out unhealthy cells, then receive the new stem cells, and take medications to prevent complications. Umbilical cord blood has been used in the treatment of various diseases, including leukemias, lymphomas, and immune system disorders.
IDH1 Inhibitor
AG-120 for Blood Cancers
Recruiting1 awardPhase 1
Birmingham, Alabama
This trial is testing a new drug, AG-120, to see if it's safe and effective in treating people with advanced cancers that have a mutation in the IDH1 gene. The trial has two parts: first, they'll test different doses of the drug to see what the maximum tolerated dose is; then, they'll expand the trial to a larger group of people to see if the drug is effective. There's also a substudy testing AG-120 in people with a different but related cancer, myelodysplastic syndrome.
Trials for Myelomonocytic Leukemia Patients
Antimetabolites
Cord Blood Transplant for Blood Diseases
Recruiting1 awardPhase 1
Rochester, New York
This trial uses stem cells from a baby's umbilical cord to treat patients who need new healthy stem cells. Patients first get strong medicine to clear out unhealthy cells, then receive the new stem cells, and take medications to prevent complications. Umbilical cord blood has been used in the treatment of various diseases, including leukemias, lymphomas, and immune system disorders.
IDH1 Inhibitor
AG-120 for Blood Cancers
Recruiting1 awardPhase 1
Birmingham, Alabama
This trial is testing a new drug, AG-120, to see if it's safe and effective in treating people with advanced cancers that have a mutation in the IDH1 gene. The trial has two parts: first, they'll test different doses of the drug to see what the maximum tolerated dose is; then, they'll expand the trial to a larger group of people to see if the drug is effective. There's also a substudy testing AG-120 in people with a different but related cancer, myelodysplastic syndrome.
Trials for HLA-A Positive Patients
CAR T-cell Therapy
Gene Modified T-cells for Blood Disorders
Recruiting1 awardPhase 1 & 2
Los Angeles, California
This trial will look at whether T cells from a family member can help a patient's immune system recover after a stem cell transplant, with the added safety measure of a self-destruct switch.
Alkylating agents
Bone Marrow Transplant for Blood Cancers
Recruiting1 awardPhase 2
Tampa, Florida
This trial tests a stem cell transplant for patients who need a transplant but don't have a perfect match. The process uses a less intense preparation method and aims to see if patients remain disease-free over time.
Chemotherapy
Treg-Enriched Stem Cell Transplant for Leukemia
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is studying a new way to give a haploidentical stem cell transplant (using donor cells that have been enriched with regulatory T cells) to people with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
Procedure
Experimental Drug for Leukemia Post-Stem Cell Transplant
Recruiting1 awardPhase 1
New York, New York
This trial is testing two different doses of an experimental drug to see if it is safe and effective in treating patients with leukemia who have received a stem cell transplant from a related donor.
Phase 3 Trials
Protein Therapeutics
Luspatercept vs Epoetin Alfa for MDS-related Anemia
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial will compare luspatercept to epoetin alfa to see if luspatercept is more effective in increasing hemoglobin and reducing the need for RBC transfusions in patients with anemia due to MDS.
Anti-metabolites
Cedazuridine + Azacitidine for Leukemia
Recruiting1 awardPhase 2 & 3
Hackensack, New Jersey
This trial tests a new pill form of two drugs, cedazuridine and azacitidine, for patients needing azacitidine treatment. The goal is to see if the pill is as effective as the injection. Cedazuridine helps azacitidine work better by preventing its breakdown, and azacitidine stops cancer cells from growing.
Cancer Treatment
Epoetin Alfa vs Luspatercept for Myelodysplastic Syndrome
Recruiting2 awardsPhase 3
Concord, California
This trial is testing two treatments, Luspatercept and epoetin alfa, to see which is better for treating anemia in adults with certain types of myelodysplastic syndromes (MDS). The participants have not used similar treatments before and do not need regular blood transfusions. Luspatercept helps red blood cells mature, while epoetin alfa increases their production.
Trials With No Placebo
Antimetabolites
Cord Blood Transplant for Blood Diseases
Recruiting1 awardPhase 1
Rochester, New York
This trial uses stem cells from a baby's umbilical cord to treat patients who need new healthy stem cells. Patients first get strong medicine to clear out unhealthy cells, then receive the new stem cells, and take medications to prevent complications. Umbilical cord blood has been used in the treatment of various diseases, including leukemias, lymphomas, and immune system disorders.
IDH1 Inhibitor
AG-120 for Blood Cancers
Recruiting1 awardPhase 1
Birmingham, Alabama
This trial is testing a new drug, AG-120, to see if it's safe and effective in treating people with advanced cancers that have a mutation in the IDH1 gene. The trial has two parts: first, they'll test different doses of the drug to see what the maximum tolerated dose is; then, they'll expand the trial to a larger group of people to see if the drug is effective. There's also a substudy testing AG-120 in people with a different but related cancer, myelodysplastic syndrome.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.